Quintiles launches Kun Tuo CRO in China
Will develop customised solutions to assist registration of new medicines in China
Quintiles has established Kun Tuo in China, a local contract research organisation (CRO) built to service the needs of the Chinese biopharmaceutical industry and multinational biopharma companies operating in the region.
Building on Quintiles’ experience in conducting clinical trials in China since 1997, Kun Tuo will focus on developing customised solutions to help local and global biopharma companies achieve successful registration of new medicines in China.
The new CRO will provide a full range of services, including clinical trial management, regulatory submission preparation, biostatistics and data management. It will tap into Quintiles’ global resources and expertise to develop customised offerings in key therapeutic areas, along with vaccines, late phase studies, medical devices and diagnostics.
‘We have an aggressive growth plan for China and anticipate doubling Quintiles’ total staff during 2012 as we look to provide our customers with the solutions they need to succeed in one of the world’s most dynamic marketplaces,’ said Ling Zhen, general manager of Quintiles China, which employs more than 300 people, covering all population centres and study sites in China.